Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
378 Amivantamab, a bispecific antibody targeting EGFR and MET, addresses the limitations of monotargeted inhibitors and is approved for advanced or metastatic NSCLC with EGFR exon 20 insertions
Injections have shown to be much more effective, but some patients may prefer oral doses depending on their individual needs
Poor gut motility may lead to: Increased inflammation Altered gut bacteria balance Fatigue and nutrient malabsorption Weight-loss plateaus despite proper dosing In functional medicine, digestion is considered foundational
Shake ampoule well before use
Cells were dissociated with Accutase and resuspended in PBS with 3% BSA
US$ 27.56
US$ 21.26
US$ 27.61
US$ 22.61
US$ 23.38
